5 Conclusion:
Overall, the results presented are encouraging and provide clear evidence that exploring the subregional mechanisms of mPFC is of great significance for further understanding the pathogenesis and treatment of depression. In ICV-STZ rats, IDO is activated either in PrL or in IL, but the mechanisms involved in the regulation of depressive behaviors of the two subregions are obviously different. 1-MT, a selective inhibitor of IDO, can reverse ICV-STZ-induced depressive behavior by ameliorating astrocyte defects in the PrL or inhibiting IL microglial hyperactivation. These findings provide valuable information for further understanding the pathogenesis of depression and discovering a novel target for depression treatment.